Showing results (101-110 of 229) with videos related to
Sort By:
Pageof 23
JTO Clinical and Research Reports|July 31, 2023
B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung AdenocarcinomaIbiayi Dagogo-Jack, Ivan Valiev, Nikita Kotlov, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN StudyBruce D Cheson, Neil Chua, Jiri Mayer, et al.Cytometry. Part a : the Journal of the International Society for Analytical Cytology|June 15, 2021
Detecting Förster resonance energy transfer in living cells by conventional and spectral flow cytometryJared Henderson, Ondrej Havranek, Man Chun John Ma, et al.Biochimica Et Biophysica Acta|December 26, 2015
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cellsPeter P Ruvolo, Vivian R Ruvolo, Christopher B Benton, et al.The Lancet. Oncology|June 28, 2016
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialLaurie H Sehn, Neil Chua, Jiri Mayer, et al.Blood|December 18, 2010
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expressionChristina M Annunziata, Lidia Hernandez, R Eric Davis, et al.Molecular Cancer Research : MCR|August 25, 2017
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic LeukemiaHima V Vangapandu, Ondrej Havranek, Mary L Ayres, et al.Hemasphere|November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaSteven E Coutre, Ian W Flinn, Sven de Vos, et al.British Journal of Haematology|April 7, 2017
Characteristics, management, and outcomes of patients with follicular dendritic cell sarcomaPreetesh Jain, Sarah A Milgrom, Keyur P Patel, et al.Cell Reports. Medicine|August 20, 2025
AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinomaDanil Stupichev, Natalia Miheecheva, Ekaterina Postovalova, et al.Pageof 23